Mylan merger with Pfizer's Upjohn raises competition concerns, New Zealand regulator warns
MLex Summary: The merger of US-based pharmaceutical company Mylan and Pfizer subsidiary Upjohn is continuing to raise regulatory concerns in New Zealand, with the competition watchdog today suggesting that it feared...To view the full article, register now.
Already a subscriber? Click here to view full article